Korro Bio Q1 net loss $19.6M; appoints Kemi Olugemo as CMO; cash $138.8M plus $70M PIPE

Korro Bio, Inc.

2024-Q1 EPS reported -$2.44

Net loss $19.6M in Q1 2024, unchanged from Q1 2023; R&D $13.6M, G&A $7.9M.
Cash $138.8M at Mar 31, 2024; after $70M April PIPE, pro forma ~$206M; runway into H2 2026.
Appointed Kemi Olugemo, MD, as Chief Medical Officer; she brings >10 yrs industry experience.
Regulatory filing for KRRO-110 (RNA editing for AATD) on track for H2 2024; interim data H2 2025.
$70M PIPE led by Deep Track Capital with Atlas Venture, NEA, and other healthcare investors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Korro Bio, Inc. reported first quarter of 2024 results: net income $19.6 million.

Period: first quarter of 2024
Net income: $19.6 million
Result: reported results

Exact text from the filing

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.